Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma.
Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncol Lett. 2020 Feb;19(2):1175-1186 Authors: Qi F, Wang L, Huang P, Zhao Z, Yang B, Xia J Abstract Cytokines play an important role in the development of tumors. The purpose of the present study was to evaluate the mechanisms and cytokine level changes after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). The Short Time-series Expression Miner (STEM) program was utilized to cluster cytokine expression profiles from the day before TACE to day 21 post-TACE. Based on the identified significant signatures, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed. Cytokines were serially monitored in 60 evaluable patients to identify the results of the STEM program. Examination of the significant signatures identified 6 significant time-varied expression patterns for 507 cytokines (profiles 16, 18, 28, 41, 42 and 43). GO analysis was enriched in 'cytokine receptor-binding' and 'cytokine receptor activity', and the identified signaling pathways included 'cytokine-cytokine receptor interaction' and the 'JAK-STAT signaling pathway'. Ciliary neurotrophic factor (CNTF) level was increased early after TACE, reaching a peak on day 7 before finally decreasing from day 14 onwards, and was significantly positively correlated with aminotransferase level. Serum levels o...
Publication date: Available online 25 February 2020Source: Clinica Chimica ActaAuthor(s): Juan Zhou, Xinxin Zhang, Huifang Tang, Jia Yu, Xuyu Zu, Zhizhong Xie, Xiaoyan Yang, Juan Hu, Fang Tan, Qing Li, Xiaoyong Lei
Conclusions: In conclusion, BCLC staging is the main prognostic factor of survival in patients with TM who develop HCC, with a median survival time of six months.
CONCLUSION: In summary, circ-PRMT5 might play a key role in proliferation, migration, glycolysis of HCC cells via miR-188-5p/HK2 axis, which indicated that circ-PRMT5 might be a potential therapeutic target for HCC treatment. PMID: 32089501 [PubMed - as supplied by publisher]
CONCLUSIONS: TACE with CBATO is more effective and equally tolerant compared with cTACE in treating unresectable HCC patients. PMID: 32096197 [PubMed - in process]
CONCLUSIONS: The hsa_circ_0011946 could enhance cell migration and invasion of HCC by inducing the EMT process. PMID: 32096173 [PubMed - in process]
This article presents a comprehensive review of current knowledge regarding the posttransplant management of patients with hepatocellular carcinoma.American Journal of Transplantation
CONCLUSIONS AGGF1 was a potential diagnostic and prognostic marker for poor clinical outcomes in HCC patients. Moreover, vital pathways regulated by AGGF1 in HCC may include regulation of autophagy, Wnt signaling pathway, pathway in cancer, cell cycle, and P53 signaling pathway. PMID: 32090983 [PubMed - in process]
Authors: Zeng Z, Dong J, Li Y, Dong Z, Liu Z, Huang J, Wang Y, Zhen Y, Lu Y Abstract Background: Involvements of microRNA-22 (miR-22) in cancer have attracted much attention, but its role in diagnosis of hepatocellular carcinoma (HCC) is still largely unknown. Therefore, the aim of this study was to investigate the expression level and the prognostic value of miR-22 in HCC patients.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to evaluate serum level of miR-22 in 108 HCC patients and 67 healthy controls. The relationship between miR-22 expression level and clinicopathologic chara...
Publication date: Available online 24 February 2020Source: Polymer Degradation and StabilityAuthor(s): Yutaka Okamoto, Terumitsu Hasebe, Kenta Bito, Kosaku Yano, Tomohiro Matsumoto, Kosuke Tomita, Atsushi Hotta
We appreciate Dr. Brown ’s interest in our recent study (1) on transarterial chemoembolization followed by radiofrequency (RF) ablation for hepatocellular carcinoma, and we appreciate her comments. In our study, the delayed treatment was determined before the initial transarterial chemoembolization procedure. We enrolled 135 patients with a single recurrent hepatocellular carcinoma (> 3 cm) or multiple (2 –5 tumors) recurrent hepatocellular carcinomas who underwent transarterial chemoembolization plus RF ablation from 2007 to 2015 in a single-center retrospective study.